Zacks Investment Research cut shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a sell rating in a research report report published on Thursday morning, Zacks.com reports.

According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “

Several other brokerages have also weighed in on FPRX. Guggenheim lowered Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 target price on the stock. in a research report on Friday, April 12th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research report on Monday, May 13th. Roth Capital started coverage on Forty Seven in a research report on Wednesday, May 29th. They issued a buy rating and a $28.00 target price on the stock. Wells Fargo & Co cut their target price on Cummins from $175.00 to $165.00 and set a market perform rating on the stock in a research report on Monday, June 3rd. Finally, BidaskClub raised Winmark from a sell rating to a hold rating in a research report on Tuesday, May 14th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $20.00.

Shares of FPRX opened at $5.66 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.41 and a current ratio of 10.41. The business has a fifty day moving average price of $6.69. Five Prime Therapeutics has a twelve month low of $5.55 and a twelve month high of $17.80.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.05. The business had revenue of $5.35 million for the quarter, compared to analyst estimates of $5.71 million. Five Prime Therapeutics had a negative return on equity of 54.87% and a negative net margin of 683.89%. Equities research analysts expect that Five Prime Therapeutics will post -3.67 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Five Prime Therapeutics by 42.1% during the 4th quarter. Rhumbline Advisers now owns 48,640 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 14,412 shares during the period. Prudential Financial Inc. grew its stake in shares of Five Prime Therapeutics by 39.7% during the 4th quarter. Prudential Financial Inc. now owns 233,021 shares of the biotechnology company’s stock valued at $2,167,000 after purchasing an additional 66,231 shares during the period. BlackRock Inc. grew its stake in shares of Five Prime Therapeutics by 4.4% during the 4th quarter. BlackRock Inc. now owns 3,039,915 shares of the biotechnology company’s stock valued at $28,269,000 after acquiring an additional 127,777 shares during the period. Citigroup Inc. grew its stake in shares of Five Prime Therapeutics by 161.3% during the 4th quarter. Citigroup Inc. now owns 139,875 shares of the biotechnology company’s stock valued at $1,301,000 after acquiring an additional 86,347 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Five Prime Therapeutics by 0.5% during the 4th quarter. Northern Trust Corp now owns 425,775 shares of the biotechnology company’s stock valued at $3,959,000 after acquiring an additional 2,278 shares during the period. 86.91% of the stock is currently owned by institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Further Reading: Is it Safe to Invest in Commodities?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.